Compare BTCS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTCS | STRO |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 85.0M |
| IPO Year | 2008 | N/A |
| Metric | BTCS | STRO |
|---|---|---|
| Price | $1.84 | $24.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $18.88 |
| AVG Volume (30 Days) | ★ 758.9K | 139.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $4,073,518.00 | N/A |
| Revenue This Year | $248.05 | $63.08 |
| Revenue Next Year | $41.01 | N/A |
| P/E Ratio | $1.19 | ★ N/A |
| Revenue Growth | ★ 204.08 | N/A |
| 52 Week Low | $1.27 | $0.52 |
| 52 Week High | $8.49 | $25.68 |
| Indicator | BTCS | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 77.95 |
| Support Level | $1.46 | $0.76 |
| Resistance Level | $3.13 | N/A |
| Average True Range (ATR) | 0.14 | 2.05 |
| MACD | 0.07 | 0.46 |
| Stochastic Oscillator | 73.54 | 92.12 |
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.